Research

Hormonal

GLP-1 receptor agonists (liraglutide 3 mg and semaglutide 2.4 mg) produce significantly greater weight loss in patients with obesity compared to orlistat, with average losses of 7 kg more than control groups in meta-analyses.

If you have obesity and a related health condition (like diabetes or high blood pressure), GLP-1 medications (liraglutide or semaglutide) are significantly more effective for weight loss than older drugs like orlistat. You must combine the medication with a healthy diet and exercise. Start with the lowest dose and increase slowly to minimize stomach upset, which usually goes away.

GoodSupportsHIGH confidence
Los resultados de ensayos y vida real demuestran que esta medicación consigue mayores pérdidas de peso que orlistat... En un metanálisis con más de 10.000 pacientes con obesidad se vio que los tratados con arGLP-1 perdían, en promedio, 7 kg más que los que integraban los grupos control.
Eva Vilarrasa et al. · Actas Dermo-Sifiliográficas · 2023

Why this rating

Based on large-scale meta-analyses (>10,000 patients) and Phase 3 trials (SCALE, STEP), though specific long-term data for dermatological outcomes is limited.

Source

Agonistas del receptor de GLP-1 para el tratamiento de la obesidad en pacientes con dermatosis inmunomediadas

Eva Vilarrasa et al. · Actas Dermo-Sifiliográficas · 2023

DOI 10.1016/j.ad.2023.06.017

narrative_reviewCited 13×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →